We speculate, if M(IL4)s suppress inflammation-associated CRC (i.e. fewer larger tumors) this may require the presence of the cells and could be accomplished with repeated M(IL4) administrations: a possibility worthy of testing in future analyses. The gene discussed is IL4; the disease is colorectal carcinoma.